Research programme: influenza A virus H7N9 vaccine - Replikins

Drug Profile

Research programme: influenza A virus H7N9 vaccine - Replikins

Alternative Names: H7N9 Replikin peptide vaccine; H7N9 Synthetic Replikins Vaccine

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Replikins
  • Class Influenza A vaccines; Influenza A virus H7N9 vaccines; Influenza virus vaccines; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Influenza A virus H7N9 subtype

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Influenza-A virus H7N9 subtype(Prevention) in USA (Intranasal, Aerosol)
  • 18 Apr 2013 Research programme: influenza A virus H7N9 vaccine - Replikins is available for licensing as of 18 Apr 2013. www.replikins.com
  • 09 Apr 2013 Early research in Influenza A virus infections (H7N9 subtype)(prevention) in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top